Nasdaq

Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis

INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of Taltz® (ixekizumab) versus ...
Nasdaq

ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from TALTZ® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis

TORONTO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company announced the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of TALTZ® (ixekizumab) versus Humira® (adalimumab) in ...
WFMZ-TV

ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis

INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) presented detailed results today demonstrating Taltz ® (ixekizumab) met the primary and all major secondary endpoints in ...
WFMZ-TV

Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis

INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b /4 SPIRIT-Head-to-Head (H2H) study of Taltz ® (ixekizumab) versus ...